Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 23 Mar 2022
Government opts for additional consultation on National Medicines Policy review
24 March 2022 - The Government has heeded the calls from Medicines Australia, patient groups, health bodies, and industry by ...
Posted by Michael Wonder on 23 Mar 2022
The biggest PBMs are handling more and more of the country’s drug price negotiations
22 March 2022 - Alex Schmelzer didn’t think he’d be the most-hated person in drug pricing negotiations, but he was. ...
Posted by Michael Wonder on 23 Mar 2022
Orphazyme announces withdrawal of European marketing authorisation application for arimoclomol for the treatment of Niemann-Pick disease type C
22 March 2022 - Decision to withdraw the European marketing authorisation application comes ahead of scheduled final vote on the ...
Posted by Michael Wonder on 23 Mar 2022
StemCyte has submitted its application for a biologics license for its allogeneic umbilical cord haematopoietic progenitor cell product "HPC-Cord Blood", to the US FDA
22 March 2022 - The BLA has been accepted for quality review and StemCyte anticipates licensure in 2023 ...
Posted by Michael Wonder on 23 Mar 2022
MorphoSys and Incyte announce Swissmedic temporary approval of Minjuvi (tafasitamab) in combination with lenalidomide for the treatment of adults with r/r DLBCL
22 March 2022 - Minjuvi is a new therapeutic option for eligible DLBCL patients in Switzerland addressing an urgent unmet medical ...
Posted by Michael Wonder on 23 Mar 2022
Medicago, Philip Morris and Health Canada: a predictable and avoidable fiasco
22 March 2022 - Health groups urge the Federal government to pressure Medicago to align its approach with that of ...
Posted by Michael Wonder on 23 Mar 2022
Instrumental variables and heterogeneous treatment effects
22 March 2022 - A randomised clinical trial can be used to estimate the average treatment effect for a population. ...
Posted by Michael Wonder on 22 Mar 2022
U.S. Senate to vote this spring on lowering insulin prices - Senator Schumer
23 March 2022 - U.S. Senate Majority Leader Chuck Schumer said on Tuesday he intends to hold votes this spring ...
Posted by Michael Wonder on 22 Mar 2022
Prescription medicines: new or extended uses, or new combinations of registered medicines (February 2022)
22 March 2022 - The TGA approved a new indication for 7 medicines and one vaccine in February. ...
Posted by Michael Wonder on 22 Mar 2022
Pharmacy benefit managers are the wrong target In Biden’s quest to reduce drug prices
21 March 2022 - Prescription drug prices remain high despite the fact that the Biden Administration—and its predecessors—have declared reducing prices ...
Posted by Michael Wonder on 22 Mar 2022
High US drug prices have global implications
22 March 2022 - Lower income countries need better protection from an unfettered US market. ...
Posted by Michael Wonder on 22 Mar 2022
Valeo Pharma secures additional public reimbursement for Redesca, Enerzair Breezhaler and Atectura Breezhaler
22 March 2022 - Canadian provincial public reimbursement now complete for Redesca with the addition of British Columbia. ...
Posted by Michael Wonder on 22 Mar 2022
Doctors break rules for prescribing safe-sex drug as PHARMAC considers change
22 March 2022 - Doctors flagrantly broke rules for prescribing a safe-sex drug during 2021 COVID-19 lockdowns. ...
Posted by Michael Wonder on 22 Mar 2022
Hope for quadriplegics as ‘miracle treatment’ gets green light from regulator
21 March 2022 - In a major step forward for treating victims of paralysis, Australian regenerative medicine company Orthocell has ...
Posted by Michael Wonder on 22 Mar 2022
Ascentage Pharma's MDM2-p53 inhibitor alrizomadlin (APG-115) granted rare paediatric disease designation by the US FDA for the treatment of neuroblastoma
21 March 2022 - Ascentage Pharma today announced that its novel MDM2-p53 inhibitor, alrizomadlin (APG-115), was granted a rare paediatric disease ...